RxDoctor Payments Data

Todd Locke, MD

Internal Medicine · South Euclid, OHNPI 1457447682

Payments from drug & device makers

$8,777in general payments, 2019–2025

Across 511 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • AstraZeneca$575
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$533
  • Astellas Pharma US Inc$528
  • Novo Nordisk$364
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$8,71199%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,777 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$87,869
Medicare patients
241
Services billed
1,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$82,745
MyrbetriqMirabegron20$14,942
JardianceEmpagliflozin12$7,209
SynthroidLevothyroxine Sodium66$5,212
Hydrocortisone11$3,764
Rosuvastatin Calcium92$3,425
Ezetimibe25$2,732
Tamsulosin Hcl82$1,923
Atorvastatin Calcium131$1,797
PaxlovidNirmatrelvir/Ritonavir12$1,429
Metoprolol Succinate106$1,286
Celecoxib18$1,083
Escitalopram Oxalate57$1,030
Esomeprazole Magnesium22$907
Omeprazole53$786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$294$84,17589 claims
Astellas Pharma US IncMyrbetriq$528$14,94220 claims
Boehringer IngelheimJardiance$69$7,20912 claims
AbbVieSynthroid$2,162$5,21266 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in South Euclid

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →